Obagi Medical, a part of Waldencast (WALD), announced VIO Med Spa as a launch partner for the Aesthetics Leadership with Obagi’s Hyaluronic Acid, ALOHA, Program. “VIO Med Spa was selected for its rapid growth, expert-led approach to advanced aesthetic treatments, and dedication to delivering high-quality, results-driven care across its expanding national network of locations,” the company said.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WALD:
- Obagi Medical, Next Health collaborate for ALOHA program
- Obagi Medical, Alpha Aesthetic Partners collaborate for ALOHA program
- Obagi Medical, Platinum Dermatology Partners collaborate for ALOHA program
- Obagi Medical unveils ALOHA Program to launch saypha MagIQ
- Waldencast Shareholders Back Board Slate and Auditor at January 2026 AGM